impf-info.de
Nachdem Covid19 aus medizinischer Sicht "durch" ist, hier jetzt also wieder das Thema Impfen in ganzer Breite...
FDA: GSKs Sotrovimab in zugelassener Dosierung wohl unwirksam gegen BA.2
FDA says current dose of GSK-Vir COVID therapy unlikely to work against BA.2 variant | Reuters
The U.S. health regulator said on Friday the current authorized dose of GlaxoSmithKline and Vir Biotechnology's COVID-19 antibody therapy is unlikely to be effective against the Omicron BA.2 variant.
By accepting you will be accessing a service provided by a third-party external to https://www.impf-info.de/
